iTeos Therapeutics, a Phase 1/2 immuno-oncology biotech developing therapies for various cancers, raised $201 million by offering 10.6 million shares at $19, above the range of $16 to $18. The company originally planned to offer 8.9 million shares. At pricing, iTeos commands a fully diluted market cap of $681 million.
iTeos Therapeutics plans to list on the Nasdaq under the symbol ITOS. J.P. Morgan, SVB Leerink and Piper Sandler acted as lead managers on the deal.
